The DeSci Podcast

Michael Baran, Executive Director at WRDM and partner at Pfizer Ventures, delves into the revolutionary potential of decentralized science (DeSci). He explores how DeSci is redefining traditional biotech paradigms and enhancing investment models through decentralized autonomous organizations (DAOs). Michael discusses the risks in early-stage science investments, challenges in biopharma, and common misconceptions about the sector. He emphasizes the importance of maintaining scientific quality while navigating the complexities of innovation and funding in the evolving landscape.

Dr. Jocelynn Pearl, biotech scientist and co-founder of LabDAO, discusses the birth of Decentralized Biotech, the importance of incentivizing knowledge sharing, pros and cons of centralization in Biotech, limits of online collaboration, sharing tacit knowledge, funding for good projects, and contentious topics within LabDAO.

Juan Benet, Founder of Protocol Labs, discusses the translational science problem, cryptocurrency's impact on research, and the intersection of AI and future society.

Join Niklas Anzinger as he discusses investing in network states, startup cities, and over-regulated industries on this episode. Learn about Infinitia Funds, Prospera's mission, and the need for improved regulatory systems. Explore projects like Zuzalu focusing on extending human lifespans and enhancing health outcomes. Discover the potential for growth and innovation in fields like Longevity and Science through Network States and Startup Cities.

Welcome to another episode of the DeSci Podcast. Today, we were joined by Jesse Hudson, the Chief Legal Architect at Molecule, Chris Byrnes, an IP Legal Advisor also representing Molecule, and Benji Leibowitz, Product Manager at Molecule. The existing intellectual property (IP) system faces several challenges that hinder its effectiveness and innovation potential. Patent trolls, the system's lack of efficiency, and the high transaction costs associated with acquiring and enforcing IP rights further burden inventors, researchers, and scientific enterprises. In this episode, we explore the groundbreaking concept of IP Tokens and how they can help solve the issues plaguing the current IP system. We explain what IP Tokens are and how they differentiate from IP-NFTs. We also discuss how IP tokens could facilitate scientific entrepreneurship and how they open up decentralization in science by enabling a system where the community can partake in the governance processes. Navigate the various topics covered in the Podcast using the timestamps below. ____ ⭐ Timestamps: 0:00 Intro 2:11 About Jesse Hudson 2:54 About Chris Byrnes 5:47 Fundamental issues within the IP system 11:16 How Molecule facilitates Scientific entrepreneurship 20:12 Overview of Intellectual Property 32:09 What is an IP-NFT? 37:05 IP Tokens and why they matter. 51:11 Digitizing the process of IP licensing 1:02:41 IP Tokens and Decentralization 1:10:16 IP financing 1:16:31 Enforcing IP rights 1:22:22 Outro ____ If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below. If you want to join us on the show as a speaker or have guest ideas, please shoot us a mail at podcast@molecule.to Special thanks to: Benji Leibowitz: https://twitter.com/benjileibo Jesse Hudson: https://twitter.com/jsshdsn Chris Byrnes: https://twitter.com/reimagineIP ____ Let's connect: Website: https://bit.ly/3d6nh2C Twitter: https://twitter.com/Molecule_dao Discord: https://discord.com/invite/moleculedao

Welcome to another episode of the DeSci Podcast! Today, we were joined by Ben Reinhardt, founder of Speculative Technologies, a nonprofit research organization that runs coordinated research programs to unlock groundbreaking innovations. In this episode, we explore the qualities that make funders exceptional and the key factors that contribute to successful startup grants. We also shed light on the social and financial asymmetries between grantor and grantee, highlighting their negative impact on the funding process. Other topics we discussed are the differences between small and large grants, limitations of grant-making programs, common misconceptions between the public and private sector and many more. Feel free to navigate through any of the topics discussed in the Podcast using the timestamps below. ____ ⭐ Timestamps: 0:00 Intro 1:46 Characteristics of good funders 6:39 Key factors for successful startup grants 13:02 Asymmetries in grantor-grantee relationships 16:20 Small and large grants 19:09 Coordination in research 26:50 Pros and cons of grants 30:28 Limitations and drawbacks of grant-making programs 36:10 Common misconceptions between the public and private sector 38:07 Contentious issues within your field 42:42 Reforming science funding 44:20 How do you approach research management? 46:52 Topics Ben wants to write about 52:04 Outro ____ If you want to join us on the show as a speaker or have guest ideas, please shoot us a mail at podcast@molecule.to Special thanks to: Lea Degen (host): https://twitter.com/lealeata Ben Reinhardt: https://twitter.com/Ben_Reinhardt ____ Let's connect: Website: https://bit.ly/3d6nh2C Twitter: https://twitter.com/Molecule_dao Discord: https://discord.com/invite/moleculedao

Welcome to another episode of the DeSci Podcast! We are excited to have Nadia Asparouhova, an independent researcher and author of "Working in Public: The Making and Maintenance of Open Source Software", as our guest today. In this thought-provoking episode, we delve into the world of early-stage science funding and philanthropy. We discuss the role philanthropy plays in society and how it has evolved over the years. We also explore new funding mechanisms that have emerged to revolutionize the landscape of early-stage science, as well as the limitations and setbacks associated with these new funding mechanisms. Additionally, we discuss the political challenges of early-stage science funding and the pivotal role that government and individual patrons should play in supporting early-stage science. Please refer to the timestamps below to navigate through any of the topics discussed in the podcast. ____ ⭐ Timestamps: 00:00 Intro 01:40 The role of philanthropy. 03:16 What drove your interest in science funding? 05:00 The uniqueness of tech 06:19 Understanding early stage science 08:27 New funding mechanisms for early stage science 13:02 Limitations to the new funding mechanisms 16:09 Importance of peer review 18:25 Common misconceptions about early stage science funding 21:47 Evolution of philanthropy 27:18 Philanthropy and the government 29:35 Political Challenges of early-stage science Funding 35:25 Legitimacy in early stage science funding 41:47 Science philanthropy: Then & Now 47:23 Outro ____ If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below. If you want to join us on the show as a speaker or have guest ideas, please shoot us a mail at podcast@molecule.to Special thanks to: Lea Degen (host): https://twitter.com/lealeata Nadia: https://twitter.com/nayafia ____ Let's connect: Website: https://bit.ly/3d6nh2C Twitter: https://twitter.com/Molecule_dao Discord: https://discord.com/invite/moleculedao

Welcome to another episode of the DeSci Podcast. Today, we had the privilege of having Dr. Martin-Immanuel Bittner as our guest. He is the CEO of Arctoris, which is the world's first fully automated platform for drug discovery, focused on accelerating the drug discovery process. In this episode, we explore a variety of fascinating topics related to drug discovery. Dr. Bittner shares insights on the story behind building Arctoris and its mission to accelerate the drug discovery process. We also talk about how the drug development process has evolved over the years and the need to automate drug discovery research. Other topics discussed were challenges stemming from the lack of rigorous funding in biotech, common misconceptions about automation, and many more. Please feel free to navigate through any of the topics discussed in the podcast using the timestamps below. ____ ⭐ Timestamps: 0:38 Intro 1:18 About Arctoris 2:52 What drove your interests in building Arctoris 4:23 Learnings from running Arctoris 5:53 What area needs more focus 8:03 Common misconceptions about automation 10:01 Flexibility in automation 13:44 Underexploited areas 16:09 Antibiotic resistance problem 17:58 Funding structures for Biotech companies 20:15 Investing in Biotech 22:38 The private sector and Academia 25:00 Changing beliefs on the need of automation in drug discovery 27:08 Contentious issues within your field 29:06 Implicit knowledge in drug discovery ____ If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below. If you want to join us on the show as a speaker or have guest ideas, please shoot us a mail at podcast@molecule.to Special thanks to: Lea Degen (host): https://twitter.com/lealeata Martin: https://www.linkedin.com/in/martinimmanuelbittner/?originalSubdomain=uk ____ Let's connect: Website: https://bit.ly/3d6nh2C Twitter: https://twitter.com/Molecule_dao Discord: https://discord.com/invite/moleculedao

Martin Karlsson, CEO of Lateral, an innovative web app for scientists, discusses the best way to utilize Lateral's AI tools. We also explore the future of research, the cutting-edge capabilities of AI, and the importance of retaining human agency in the research process.

Niklas Rindtorff, co-founder of LabDAO, shares insights on conducting life science research online, benefits of collaboration within the scientific community, ownership rights in decentralized autonomous organizations, overlooked areas in decentralized science, differences in the private and public sector, and underappreciated aspects of academia.